Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

A.J. Grillo-López | Researchclopedia

Back to researchers

A.J. Grillo-López

The University of Texas MD Anderson Cancer Center

64

Works

8,902

Citations

27

h-index

30

i10-index

Research Topics

Lymphoma Diagnosis and Treatment Monoclonal and Polyclonal Antibodies Research Chronic Lymphocytic Leukemia Research

Affiliations

Northwestern University1999–1999

Fox Chase Cancer Center1994–1994

Roswell Park Comprehensive Cancer Center1999–2005

Sunnybrook Health Science Centre1998–1998

Mayo Clinic1999–1999

Top Works

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin,A.J. Grillo-López,et al.

19982,755 citations

CAR-T cell therapy research

Radiopharmaceutical Chemistry and Applications

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

M. S. Czuczman,A.J. Grillo-López,et al.

1999856 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

DG Maloney,TM Liles,et al.

1994748 citations

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

DG Maloney,A.J. Grillo-López,et al.

1997637 citations

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Neil L. Berinstein,A.J. Grillo-López,et al.

1998520 citations

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Julie M. Vose,Brian K. Link,et al.

2001416 citations

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Lawrence D. Piro,Christine A. White,et al.

1999368 citations

Complement activation plays a key role in the side‐effects of rituximab treatment

Lizet E. van der Kolk,A.J. Grillo-López,et al.

2001322 citations

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

A.J. Grillo-López,Christine A. White,et al.

1999294 citations